The other side of TNF-targeted therapy of patients with rheumatoid arthritis

Curr Rheumatol Rep. 2001 Feb;3(1):1-2. doi: 10.1007/s11926-001-0041-2.

Authors

T Abe¹, T Takeuchi

Affiliation

¹ Department of Internal Medicine, Saitama Medical Center/School, Kamoda, Kawagoe-shi, Saitama 350-8550, Japan. [email protected]

PMID: 11177764
DOI: 10.1007/s11926-001-0041-2

No abstract available

MeSH terms

Antibodies, Monoclonal / administration & dosage
Antibodies, Monoclonal / therapeutic use
Antirheumatic Agents / therapeutic use
Arthritis, Rheumatoid / drug therapy*
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Dose-Response Relationship, Drug
Humans
Infliximab
Japan / epidemiology
Methotrexate / therapeutic use
Multicenter Studies as Topic
Treatment Outcome
Tumor Necrosis Factor-alpha / drug effects*

Substances

Antibodies, Monoclonal
Antirheumatic Agents
Tumor Necrosis Factor-alpha
Infliximab
Methotrexate